| EPO (n = 68) | Placebo (n = 70) |  |
---|---|---|---|
Death; n(%) | 8 (11.8) | 6 (8.6) | p = 0.53 |
MI; n(%) | 4 (5.9) | 2 (2.9) | p = 0.38 |
Death or MI; n(%) | 10 (14.7) | 7 (10.0) | p = 0.40 |
Stroke; n(%) | 1 (1.5) | 0 (0) | p = 0.31 |
Death or MI or Stroke; n(%) | 10 (14.7) | 7 (10.0) | p = 0.40 |
Coronary bypass surgery; n(%) | 1 (1.5) | 0 (0) | p = 0.31 |
Target lession revascularization; n(%) | 15 (22.1) | 9 (12.9) | p = 0.15 |
MACE; n(%) | 17 (25.0) | 12 (17.1) | p = 0.26 |